The distribution of new enhancing lesion counts in multiple sclerosis: Further explorations

Multiple Sclerosis

Volumn 15, Issue 1, 2009, Pages 42-49

  van den Elskamp, Ivo J ^a   Knol, D L ^a   Uitdehaag, B M J ^a   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

MRI; Multiple sclerosis; Negative binomial distribution; New enhacning lesion count

Indexed keywords

BETA1A INTERFERON; PLACEBO; TEMSIROLIMUS;

ARTICLE; BINOMIAL DISTRIBUTION; BRAIN DAMAGE; CLINICAL TRIAL; FOLLOW UP; HUMAN; IMAGE DISPLAY; IMAGE ENHANCEMENT; MULTIPLE SCLEROSIS; NEGATIVE BINOMIAL DISTRIBUTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POISSON DISTRIBUTION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADOLESCENT; ADULT; BRAIN; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; YOUNG ADULT;

EID: 58149098225     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508096683     Document Type: Article

References (15)

1. Sormani MP Bruzzi P Miller DH Gasperini C Barkhof F Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: Implications for clinical trials. J Neurol Sci 1999; 163: 74-80.
2. Sormani MP Bruzzi P Rovaris M. Modelling new enhancing MRI lesion counts in multiple sclerosis. Mult Scler 2001; 7: 298-304.
3. Miller DH Albert PS Barkhof F. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16.
4. Polman C Barkhof F Kappos L. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: A double-blind randomized study. Mult Scler 2003; 9: 342-348.
5. Kappos L Barkhof F Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: Results from a randomised, controlled clinical trial. J Neurol 2005; 252(Suppl. 2): 46 (abstract 158).
6. Comi G Filippi M Wolinsky JS; and the Europian Canadian Glatiramer Acetate Study Group. Europian/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.
7. Li DK Paty DW.; and the UBC MS/MRI analysis research group and the PRISMS study group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206.
8. Johnson NL Kotz S Kemp AW. Univariate discrete distributions. 2nd ed. New York: Wiley; 1993.
9. Puig P Valero J. Count data distributions: Some characterizations with applications. J Am Stat Assoc 2006; 101: 332-340.
10. Karlis D. A general EM approach for maximum likelihood estimation in mixed Poisson regression models. Stat Modelling 2001; 1: 305-318.
11. Bulmer MG. On fitting the Poisson lognormal distribution to species-abundance data. Biometrics 1974; 30: 101-110.
12. Xu XM Robinson J. Modelling the effects of wetness duration and fruit maturity on infection of apple fruits of Cox's Orange Pippin and two clones of Gala by Venturia inaequalis. Plant Pathol 2005; 54: 347-356.
13. Massé JC Theodorescu R. Neyman type a distribution revisited. Stat Neerl 2005; 59: 206-213.
14. Carpenter J Bithell J. Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Stat Med 2000; 19: 1141-1164.
15. Altman RM Petkau AJ. Application of hidden Markov models to multiple sclerosis lesion count data. Stat Med 2005; 24: 2335-2344.